{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T20:21:01Z","timestamp":1789762861058,"version":"4.0.1"},"reference-count":12,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.critrevonc.2017.02.023","type":"journal-article","created":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T03:55:44Z","timestamp":1488340544000},"page":"18-21","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Is still there a place for orteronel in management of prostate cancer? Data from a literature based meta-analysis of randomized trials"],"prefix":"10.1016","volume":"113","author":[{"given":"Giandomenico","family":"Roviello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Pacifico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Chiriac\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Generali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"July (4)","key":"10.1016\/j.critrevonc.2017.02.023_bib0005","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1177\/1758834016642370","article-title":"CYP17 inhibitors in prostate cancer: latest evidence and clinical potential","volume":"8","author":"Alex","year":"2016","journal-title":"Ther. Adv. Med. Oncol."},{"issue":"December (10)","key":"10.1016\/j.critrevonc.2017.02.023_bib0010","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/j.ctrv.2015.08.002","article-title":"Understanding and overcoming the mechanisms of primary and acquired resistance to abiraterone and enzalutamide in castration resistant prostate cancer","volume":"41","author":"Buttigliero","year":"2015","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.critrevonc.2017.02.023_bib0015","first-page":"25","article-title":"Swiss group for clinical cancer research SAKK. orteronel switch maintenance therapy in metastatic castration resistant prostate cancer after first-line docetaxel: a multicenter, randomized, double-blind, placebo-controlled trial (SAKK 08 \/11)","author":"Cathomas","year":"2016","journal-title":"Prostate"},{"key":"10.1016\/j.critrevonc.2017.02.023_bib0020","doi-asserted-by":"crossref","first-page":"5042","DOI":"10.1200\/jco.2014.32.15_suppl.5042","article-title":"Regional differences observed in the phase 3 trial (ELM-PC 5) with orteronel (TAK-700) plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed during or following docetaxel","volume":"32","author":"Fizazi","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"March (7)","key":"10.1016\/j.critrevonc.2017.02.023_bib0025","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1200\/JCO.2014.56.5119","volume":"33","author":"Fizazi","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2017.02.023_bib0030","series-title":"Estimated Cancer Incidence, Mortality and Prevalence Worldwidein 2012","author":"GLOBOCAN","year":"2012"},{"issue":"September (2\u20133)","key":"10.1016\/j.critrevonc.2017.02.023_bib0035","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s10555-013-9473-1","article-title":"Metastatic castration-resistant prostate cancer (CRPC): preclinical and clinical evidence for the sequential use of novel therapeutics","volume":"33","author":"Mukherji","year":"2014","journal-title":"Cancer Metastasis Rev."},{"issue":"May (5)","key":"10.1016\/j.critrevonc.2017.02.023_bib0040","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1093\/annonc\/mdr414","article-title":"Gondos A. EUNICE Survival Working Group. Changes in incidence, survival and mortality of prostate cancer in Europe and the United States in the PSA era: additional diagnoses and avoided deaths","volume":"23","author":"Neppl-Huber","year":"2012","journal-title":"Ann. Oncol."},{"issue":"May (61)","key":"10.1016\/j.critrevonc.2017.02.023_bib0045","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ejca.2016.04.002","article-title":"Role of the novel generation of androgen receptor pathway targeted agents in the management of castration-resistant prostate cancer: a literature based meta-analysis of randomized trials","volume":"6","author":"Roviello","year":"2016","journal-title":"Eur. J. Cancer"},{"issue":"May","key":"10.1016\/j.critrevonc.2017.02.023_bib0050","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.critrevonc.2016.02.013","article-title":"Incidence and relative risk of adverse events of special interest in patients with castration resistant prostate cancer treated with CYP-17 inhibitors: a meta-analysis of published trials","volume":"101","author":"Roviello","year":"2016","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"March (3)","key":"10.1016\/j.critrevonc.2017.02.023_bib0055","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/S1470-2045(15)70027-6","article-title":"ELM-PC 4 investigators. Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial","volume":"16","author":"Saad","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2017.02.023_bib0060","doi-asserted-by":"crossref","first-page":"8253","DOI":"10.1200\/JCO.2005.03.4777","article-title":"Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgenreceptor signaling axis","volume":"23","author":"Scher","year":"2005","journal-title":"J. Clin. Oncol."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842816303146?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842816303146?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T12:09:51Z","timestamp":1692706191000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842816303146"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":12,"alternative-id":["S1040842816303146"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2017.02.023","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Is still there a place for orteronel in management of prostate cancer? Data from a literature based meta-analysis of randomized trials","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2017.02.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}